Navigation Links
Xencor Reports Second Quarter 2014 Financial Results
Date:7/31/2014

me period of 2013. For the six months ended June 30, 2014, net loss was $8.8 million, or $(0.28) on a fully diluted per share basis, compared to a net loss of $54.7 million, or $(4.35) on a fully diluted per basis for the same period in 2013. The lower loss on a per share basis in the three and six month periods ended June 30, 2014 compared to the same periods in 2013 are primarily due to a non-cash expense of $48.6 million related to the loss on the settlement of convertible notes that is reflected in the 2013 losses and the additional shares reflected in the 2014 per share calculations as a result of the Company's IPO in December 2013.

Cash balance totaled $66.2 million as of June 30, 2014, compared to $78.0 million on December 31, 2013.

Financial GuidanceBased on current operating plans, Xencor expects to have sufficient cash to fund research and development programs and operations through 2016, and maintains the 2014 year-end cash and cash equivalents estimate of approximately $54.0 million.

Conference Call and WebcastXencor will host a conference call today at 4:30 p.m. EDT to discuss these second quarter 2014 financial results and provide a corporate update.

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers, and providing the conference ID number 74824866. A live webcast of the conference call will be available online from the investor relations section of the Company's website at www.xencor.com. The webcast will be archived on the company website for 30 days.

About Xencor, Inc.  
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, seven candidates are in clinical development internally and with partners that have been engineered with Xencor's
'/>"/>

SOURCE Xencor Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call
2. Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
3. Xencor, Inc. Announces Closing of Initial Public Offering
4. Pharmacyclics Reports Second Quarter 2014 Results
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
6. Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015
7. HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013
8. Endo Reports Second Quarter Financial Results
9. Columbia Laboratories Reports Second Quarter 2014 Financial Results
10. Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
11. Hospira Reports Second-Quarter 2014 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
(Date:1/22/2015)... Inc. (NASDAQ: UPI ), a medical device company ... treat voiding dysfunctions, today reported financial results for the ... Global revenue for the Company,s Urgent ®  PC Neuromodulation ... revenue record, as compared to $3.9 million in the ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... Calif., Aug. 1, 2011 ThermoGenesis Corp. (NASDAQ: ... that process and store adult stem cells, said today that ... July 29, 2011. "Dr. Rao has been appointed ... which requires him to resign as a director of the ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERT ... customizable medical devices to biopharmaceutical and healthcare organizations ... respiratory efficacy services in drug development, announced today ... 2011.  Unless otherwise noted, all comparative numbers refer ...
Cached Medicine Technology:ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao 2ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao 3ERT Reports Second Quarter 2011 Operating Results 2ERT Reports Second Quarter 2011 Operating Results 3ERT Reports Second Quarter 2011 Operating Results 4ERT Reports Second Quarter 2011 Operating Results 5ERT Reports Second Quarter 2011 Operating Results 6ERT Reports Second Quarter 2011 Operating Results 7ERT Reports Second Quarter 2011 Operating Results 8ERT Reports Second Quarter 2011 Operating Results 9ERT Reports Second Quarter 2011 Operating Results 10ERT Reports Second Quarter 2011 Operating Results 11ERT Reports Second Quarter 2011 Operating Results 12ERT Reports Second Quarter 2011 Operating Results 13
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... Four years since the release of their debut ... the marriage of Avasa & Matthew Love – the duo are ... for release through White Swan Records on February 24, 2015. , ... sacred path available to all of us to walk out of ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... ... AZ (Vocus) December 23, 2008 -- Adding to a growing body of ... the December 23rd issue of Circulation further emphasized the need to exercise ... most Americans fall far short of the minimum recommended guidelines of physical ...
... Center for Clinical and Translational Science (CCTS) has ... third annual pilot-project grant program. The grants, which ... early studies in translational science that, if successful, ... CCTS, established through funds from a 2006 Clinical ...
... dangers, researchers say , , TUESDAY, Dec. 23 (HealthDay News) ... in the United States combine over-the-counter medications with prescription ... potentially dangerous interactions, a new survey finds. , A ... more than 175,000 emergency department visits for adverse drug ...
... sports such as swimming had greater bone density in menopause ... exercise during adolescence may help women maintain their bone strength ... Dec. 22 in the British Journal of Sports Medicine ... the teenage exercise habits of 46 postmenopausal women, now aged ...
... perihepatic capsules with concomitant pelvic inflammation. The pain ... main symptom. These cases have to be cautiously ... is pain in the right upper abdomen Fitz-Hugh-Curtis ... that can be diagnosed by non-invasive methoids and ...
... presenting cells (APCs) that both initiate and modulate the ... antigen capture and presentation to T cells, with the ... T cells. Gastric cancer is one of the most ... progress, it is still difficult to treat advanced gastric ...
Cached Medicine News:Health News:Treadmill Desks to the Rescue: Weight Control and Activity Critical in Preventing Heart Failure 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 3Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 4Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4Health News:What is the clinical character of Fitz-Hugh-Curtis syndrome? 2Health News:A new light on tumor immunotherapy for gastric cancer 2
... III, laboratory-grade pure water at a constant ... potable tap water and combine complementary purification ... is easy to operate, reliable, and allows ... a low operating cost., Applications, Glassware ...
... 10,400 more samples than traditionally-insulated freezers, ... panel technology maximizes storage capacity. Freezer ... compartments; two adjustable-height shelves included. Patented ... energy consumption and extends compressor life. ...
... Direct Heat Decontamination CO2 Incubator provides ... control of airborne contaminants. The dual ... decontamination and a 145C dry sterilization ... line changes and /or when working ...
... Simple, economical, moderate-sized CO2 incubator with ... with glass inner door, HEPA filtered ... minimize sample exposure. Simple, large character ... IR CO2 sensing and mulitple temperature ...
Medicine Products: